Last Price
0.055
Today's Change
-0.002 (3.50%)
Day's Change
0.054 - 0.057
Trading Volume
18,871,623
Market Cap
402 Million
Shares Outstanding
7 Billion
Avg Volume
22,701,329
Avg Price (50 Days)
0.07
Avg Price (200 Days)
0.09
PE Ratio
-5.50
EPS
-0.01
Earnings Announcement
23-Aug-2024
Previous Close
0.06
Open
0.06
Day's Range
0.054 - 0.057
Year Range
0.039 - 0.15
Trading Volume
18,871,623
1 Day Change
-3.51%
5 Day Change
-3.51%
1 Month Change
-17.91%
3 Month Change
-50.00%
6 Month Change
-50.00%
Ytd Change
-50.00%
1 Year Change
-40.86%
3 Year Change
-84.29%
5 Year Change
266.67%
10 Year Change
270.00%
Max Change
-99.62%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.